Serum Adiponectin Predicts COVID-19 Severity

被引:2
作者
Pavel, Vlad [1 ]
Raeth, Ulrich [1 ]
Schmid, Stephan [1 ]
Krautbauer, Sabrina [2 ]
Keller, Dennis [1 ]
Amend, Pablo [1 ]
Mueller, Martina [1 ]
Mester, Patricia [1 ]
Buechler, Christa [1 ]
机构
[1] Univ Hosp Regensburg, Dept Internal Med Gastroenterol Hepatol Endocrinol, D-93053 Regensburg, Germany
[2] Univ Hosp Regensburg, Inst Clin Chem & Lab Med, D-93053 Regensburg, Germany
关键词
adiponectin; disease severity; C-reactive protein; intensive care; bacterial superinfection; COVID-19; ADIPOSE-TISSUE; EXPRESSION; MORTALITY; MARKERS; OBESITY; SEPSIS;
D O I
10.3390/biomedicines12051043
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Adiponectin is primarily known for its protective role in metabolic diseases, and it also possesses immunoregulatory properties. Elevated levels of adiponectin have been observed in various inflammatory diseases. However, studies investigating adiponectin levels in the serum of COVID-19 patients have yielded conflicting results. This study aimed to assess serum adiponectin levels in 26 healthy controls, as well as in 64 patients with moderate and 60 patients with severe COVID-19, to determine a potential association between serum adiponectin and the severity of COVID-19. Serum adiponectin levels in severe COVID-19 patients were significantly lower than in those with moderate disease and healthy controls, who exhibited similar serum adiponectin levels. Among patients with moderate disease, positive correlations were observed between serum adiponectin and C-reactive protein levels. Of note, serum adiponectin levels of severe COVID-19 cases were comparable between patients with and without dialysis or vasopressor therapy. Superinfection with bacteria did not exert a notable influence on serum adiponectin levels in patients with severe disease. Patients who were diagnosed with severe COVID-19 and vancomycin-resistant enterococci bacteremia showed a significant reduction in their serum adiponectin levels. An analysis conducted on the entire cohort, including both moderate and severe COVID-19 patients, showed that individuals who did not survive had lower serum adiponectin levels when compared to those who survived. In summary, this study highlights a decrease in serum adiponectin levels in severe COVID-19 cases, indicating the potential utility of adiponectin as an additional biomarker for monitoring disease severity in COVID-19 or critical illnesses in general.
引用
收藏
页数:15
相关论文
共 71 条
  • [1] Precision Medicine Using Simultaneous Monitoring and Assessment with Imaging and Biomarkers to Manage Mechanical Ventilation in ARDS
    Megan Abbott
    Yuchong Li
    Laurent Brochard
    Haibo Zhang
    [J]. Intensive Care Research, 2023, 3 (3): : 195 - 203
  • [2] The potential molecular implications of adiponectin in the evolution of SARS-CoV-2: Inbuilt tendency
    Al-Kuraishy, Hayder M.
    Al-Gareeb, Ali I.
    Bungau, Simona Gabriela
    Radu, Andrei-Flavius
    Batiha, Gaber El-Saber
    [J]. JOURNAL OF KING SAUD UNIVERSITY SCIENCE, 2022, 34 (08)
  • [3] Elevated free fatty acids and impaired adiponectin bioactivity contribute to reduced SOD2 protein in monocytes of type 2 diabetes patients
    Bauer, Sabrina
    Wanninger, Josef
    Neumeier, Markus
    Wurm, Sylvia
    Weigert, Johanna
    Kopp, Andrea
    Bala, Margarita
    Schaeffler, Andreas
    Aslanidis, Charalampos
    Buechler, Christa
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2011, 90 (01) : 101 - 106
  • [4] Does the Interdependence between Oxidative Stress and Inflammation Explain the Antioxidant Paradox?
    Biswas, Subrata Kumar
    [J]. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2016, 2016
  • [5] Are adipokines the missing link between obesity, immune response, and outcomes in severe COVID-19?
    Blot, Mathieu
    Masson, David
    Nguyen, Maxime
    Bourredjem, Abderrahmane
    Binquet, Christine
    Piroth, Lionel
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2021, 45 (09) : 2126 - 2131
  • [6] SEPSIS, SEPSIS SYNDROME, AND THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) - GULLIVER IN LAPUTA
    BONE, RC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (02): : 155 - 156
  • [7] Buechler C., 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P250, DOI 10.2174/187153007782794353
  • [8] Adipokines in Liver Cirrhosis
    Buechler, Christa
    Haberl, Elisabeth M.
    Rein-Fischboeck, Lisa
    Aslanidis, Charalampos
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (07)
  • [9] Adiponectin, a key adipokine in obesity related liver diseases
    Buechler, Christa
    Wanninger, Josef
    Neumeier, Markus
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (23) : 2801 - 2811
  • [10] Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19
    Caterino, Marianna
    Gelzo, Monica
    Sol, Stefano
    Fedele, Roberta
    Annunziata, Anna
    Calabrese, Cecilia
    Fiorentino, Giuseppe
    D'Abbraccio, Maurizio
    Dell'Isola, Chiara
    Fusco, Francesco Maria
    Parrella, Roberto
    Fabbrocini, Gabriella
    Gentile, Ivan
    Andolfo, Immacolata
    Capasso, Mario
    Costanzo, Michele
    Daniele, Aurora
    Marchese, Emanuela
    Polito, Rita
    Russo, Roberta
    Missero, Caterina
    Ruoppolo, Margherita
    Castaldo, Giuseppe
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)